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Abstract
Background: Saline, the intravenous fluid most commonly administered to critically ill adults, contains a high chloride
content, which may be associated with acute kidney injury and death. Whether using balanced crystalloids rather than
saline decreases the risk of acute kidney injury and death among critically ill adults remains unknown.
Methods: The Isotonic Solutions and Major Adverse Renal Events Trial (SMART) is a pragmatic, cluster-level allocation,
cluster-level crossover trial being conducted between 1 June 2015 and 30 April 2017 in five intensive care units
at Vanderbilt University Medical Center in Nashville, TN, USA. SMART compares saline (0.9% sodium chloride)
with balanced crystalloids (clinician’s choice of lactated Ringer’s solution or Plasma-Lyte A®). Each intensive care unit is
assigned to provide either saline or balanced crystalloids each month, with the assigned crystalloid alternating monthly
over the course of the trial. All adults admitted to participating intensive care units during the study period are enrolled
and followed until hospital discharge or 30 days after enrollment. The anticipated enrollment is approximately 14,000
patients. The primary outcome is Major Adverse Kidney Events within 30 days—the composite of in-hospital
death, receipt of new renal replacement therapy, or persistent renal dysfunction (discharge creatinine ≥200%
of baseline creatinine). Secondary clinical outcomes include in-hospital mortality, intensive care unit-free days,
ventilator-free days, vasopressor-free days, and renal replacement therapy-free days. Secondary renal outcomes
include new renal replacement therapy receipt, persistent renal dysfunction, and incidence of stage 2 or higher acute
kidney injury.
Discussion: This ongoing pragmatic trial will provide the largest and most comprehensive comparison to date of
clinical outcomes with saline versus balanced crystalloids among critically ill adults.
Trial registration: For logistical reasons, SMART was prospectively registered separately for the medical ICU (SMART-
MED; ClinicalTrials.gov identifier: NCT02444988; registered on 11 May 2015; date of first patient enrollment: 1 June 2015)
and the nonmedical ICUs (SMART-SURG; ClinicalTrials.gov identifier: NCT02547779; registered on 9 September 2015;
date of first patient enrollment: 1 October 2015).
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Background
The administration of intravenous (IV) fluid is ubi-
quitous in the care of the critically ill [1]. Globally,
0.9% sodium chloride (saline) is the most common
resuscitation fluid, but recent data have associated
saline with hyperchloremia [2, 3], metabolic acidosis
and renal vasoconstriction [4, 5], acute kidney injury
(AKI) and renal replacement therapy (RRT) [6], and
increased mortality [7, 8]. Although several observa-
tional studies [7, 9–11], a before-and-after trial [6],
and meta-analyses [8, 12] suggested increased rates
of AKI, RRT receipt, and death with saline compared
with balanced crystalloids, researchers in two recent
randomized pilot trials found no difference between
crystalloids in any patient outcome [13, 14]. The
number of patients enrolled in these pilot trials was
insufficient to exclude small but potentially clinically
meaningful differences in patient outcomes between
saline and balanced crystalloids. Thus, the optimal
choice of isotonic crystalloid for the treatment of
critically ill adults remains unknown [15, 16]. To
determine the impact of balanced crystalloids com-
pared with saline on clinical outcomes among critic-
ally ill adults, a large, prospective, controlled trial is
needed [13, 17].
The aim of the present trial is to compare the effect
of balanced crystalloids with that of saline on the
development of major adverse kidney events (the
composite of death, new RRT, or persistent renal dys-
function) among intensive care unit (ICU) patients.
Secondary aims are to evaluate the effect of balanced
crystalloids with that of saline on laboratory values
(serum chloride, serum bicarbonate, serum creatinine),
organ injury (AKI, receipt of RRT), and additional
clinical outcomes (ventilator-free days, ICU-free days,
in-hospital mortality). We hypothesize that use of
balanced crystalloids among ICU patients will reduce
the incidence of major adverse kidney events.
Methods
This manuscript was written in accordance with Stand-
ard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) guidelines (see SPIRIT checklist
in Additional file 1 and Fig. 1) [18].
Design
The Isotonic Solutions and Major Adverse Renal
Events Trial (SMART) is a prospective, unblinded,
pragmatic, cluster-level allocation, cluster-level cross-
over trial being conducted between 1 June 2015 and
30 April 2017 in five ICUs at Vanderbilt University
Medical Center in Nashville, TN, USA. SMART com-
pares saline (0.9% sodium chloride) with balanced
crystalloids (lactated Ringer’s solution and Plasma-
Lyte A® [Baxter Healthcare, Deerfield, IL, USA]) with
regard to the primary outcome of Major Adverse
Kidney Events within 30 days (MAKE30)—the com-
posite of in-hospital death, receipt of new RRT, or
persistent renal dysfunction (discharge creatinine
≥200% of baseline creatinine). Consistent with the
concept of a pragmatic clinical trial [19, 20], the
eligibility criteria are broad, the sample size is large,
and study procedures are embedded into routine care
and executed by clinical personnel. The trial was
approved by the Vanderbilt University Medical Center
Institutional Review Board (IRB) with waiver of
informed consent (IRB 141349). The trial was regis-
tered with ClinicalTrials.gov prior to initiation of patient
enrollment (ClinicalTrials.gov identifiers: NCT02444988,
NCT02547779). An independent data and safety monitor-
ing board (DSMB) is monitoring the progress and safety of
the trial. The trial is investigator-initiated with funding
provided by the Vanderbilt Institute for Clinical and Trans-
lational Research through a Clinical and Translational
Science Award from the National Center for Advancing
Translational Sciences (UL1 TR000445).
Study sites and period
SMART is being conducted in five academic ICUs at
Vanderbilt University Medical Center: a 34-bed medical
ICU, a 22-bed neurological and neurosurgical ICU, a 27-
bed cardiovascular ICU, a 31-bed trauma ICU, and a 22-
bed surgical ICU. Participating ICUs began enrollment
sequentially over the first year of the study (Fig. 2). Each
ICU will enroll patients for at least 12 months and will
enroll participants for an equal number of saline and
balanced crystalloid months.
Population
All adults (aged ≥18 years) admitted to a participating
ICU at Vanderbilt University Medical Center during the
study period are enrolled at the time of ICU admission.
Enrolled patients who are discharged from the hospital
are eligible again if they are admitted to a participating
ICU again during the study period.
Consent
Saline, lactated Ringer’s solution, and Plasma-Lyte A® are
all IV crystalloids currently used in the routine care of
patients admitted to the ICUs at Vanderbilt University
Medical Center. Currently, no high-quality data suggest
that choice of crystalloid affects clinical outcomes
among critically ill adults. During the SMART trial, each
time a study crystalloid is ordered, the study confirms
that the treating clinician does not feel that a spe-
cific study crystalloid is required for the safe treatment
of that specific patient at that specific point in time (see
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Study interventions section below). The trial is felt to pose
minimal risk because (1) exposure to the study crystalloids
occurs only for patients whose treating clinician has already
decided to administer an IV crystalloid, (2) all of the crystal-
loid solutions examined are already used in routine practice
in the study environment, (3) no definitive prior data
suggest clinical outcomes are better with one crystalloid
relative to the others, and (4) the study confirms with every
crystalloid order that the treating clinician does not feel any
one crystalloid type is required for safe treatment of the
patient. Given the minimal risk, the focus of the study on
crystalloid use at an ICU level, as well as the impracticabil-
ity of consenting each patient admitted to each ICU prior
to the first administration of crystalloid, a waiver of
informed consent was granted by the Vanderbilt University
Medical Center IRB (IRB 141349).
Randomization and allocation
During each month of the study, each ICU is assigned to
either saline or balanced crystalloids. So that each ICU
would experience an equal number of months assigned
to saline and balanced crystalloids while minimizing
monthly imbalances in the hospital’s overall use of each
crystalloid, we generated two sequences of study group
assignment: (1) saline during odd-numbered months
and balanced crystalloid during even-numbered months
or (2) balanced crystalloid during odd-numbered months
and saline during even-numbered months. We planned
for three ICUs to be assigned to one sequence and the
remaining two ICUs to the opposite sequence. To facili-
tate the early administration of the assigned crystalloid
in the ED and operating room prior to the patient’s
physical arrival in the ICU, a single, computer-generated,
simple randomization was performed in which the three
ICUs that admit the majority of patients from the ED
(medical ICU, trauma ICU, and surgical ICU) were ran-
domized en bloc to one sequence of crystalloid group
assignments, and the two ICUs that admit the majority
of patients from the operating room (neurological ICU
and cardiac ICU) were randomized en bloc to the
opposite sequence of crystalloid group assignments
(Figs. 2 and 3).
Concealment and blinding
Because available laboratory values overtly reflect the























contraindications X X X X X
0.9% saline
Screening for 




receipt X X X X X
Serum electrolytes 
and creatinine X X X X X
Receipt of invasive 
support X X X X X
Clinical outcomes X
Baseline variables include: pre-study renal function; demographic characteristics, admitting location and diagnosis, 
and severity of illness at enrollment.  Intravenous fluid receipt includes: receipt of intravenous crystalloids, other 
fluids, and blood products.  Receipt of invasive support includes: receipt of RRT, mechanical ventilation, and 
vasopressors.  Clinical outcomes include: vital status, ongoing receipt of RRT, and serum creatinine at hospital 
discharge.
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist. Enrollment, interventions, and assessments. ICU
Intensive care unit
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shown high levels of provider awareness of crystalloid
assignment despite attempts at blinding [13], patients,
clinicians, and investigators are not blinded to crystalloid
assignment. All study data, including the objective pri-
mary outcome, will be electronically extracted from the
medical record in an automated manner unaffected by
study group assignment.
Study interventions
Study protocol determines only the choice of IV isotonic
crystalloid: 0.9% sodium chloride (saline group) versus the
treating clinician’s preference of lactated Ringer’s solution
or Plasma-Lyte A® (balanced crystalloid group). The com-
position of each crystalloid solution is displayed in Add-
itional file 2: Table S1. Lactated Ringer’s solution and
Plasma-Lyte A® are the balanced crystalloids commonly
available in the United States [21]. Lactated Ringer’s solu-
tion and Plasma-Lyte A® both offer a significantly lower
chloride content than saline, but other minor differences
in composition lead some clinicians to prefer one bal-
anced crystalloid or the other for particular patients;
for example, some clinicians prefer Plasma-Lyte A® over
lactated Ringer’s solution for patients receiving blood
transfusions [22]. Allowing clinicians to select either
lactated Ringer’s solution or Plasma-Lyte A® when a
balanced crystalloid is assigned is anticipated to im-
prove compliance with balanced crystalloid assignment
and emulate how balanced crystalloids are used in prac-
tice while maintaining relevant comparator groups con-
sisting of crystalloid with a higher chloride content
(saline) versus crystalloids with a lower chloride con-
tent (lactated Ringer’s solution and Plasma-Lyte A®).
Decisions regarding crystalloid rate, volume, and addi-
tive content are deferred to treating clinicians.
Delivery of the assigned crystalloid to patients occurs
via interventions in pharmacy supply and clinician order
entry. Each month, the dispensing cabinets within the
ICUs are stocked with 1000-ml bags of the assigned
crystalloid. Additionally, any order for IV crystalloid for
a patient located in a study ICU triggers an advisor
application within the electronic order entry system. The
advisor application informs providers about the study,
asks about relative contraindications to the assigned
crystalloid, and (if relative contraindications are not
present) guides providers to order the assigned crystal-
loid. Accepted relative contraindications for patients
assigned to balanced crystalloid include hyperkalemia
and brain injury. The severity of hyperkalemia and brain
injury at which saline will be used in favor of balanced
crystalloids is determined by the treating clinician. The
nonassigned crystalloid is also made available via the
pharmacy if a formal statement is submitted that the
attending physician feels the nonassigned crystalloid is
required for the safe treatment of a specific patient.
Although the study is focused on crystalloid use in the
ICU, crystalloid administration prior to ICU admission in
the emergency department (ED) or operating room may
introduce contamination and limit separation between
study arms. Therefore, between 1 January 2016 and 30
April 2017, the Vanderbilt University Medical Center ED is
coordinating their crystalloid use with the medical, surgical,
and trauma ICUs such that patients admitted to those units
from the ED begin receiving the assigned crystalloid during
evaluation and management in the ED (ClinicalTrials.gov
identifier: NCT02614040). Clinical outcomes of patients
treated with study crystalloids in the ED and hospitalized
outside the ICU will be recorded and reported separately.
Similarly, to the extent that it is logistically feasible, for
patients identified in the operating room as coming from
or being admitted to one of the participating ICUs, the
request is made that they receive the fluid assigned to the
corresponding ICU during their operative procedure.
Fluid administered prior to enrollment by the emer-
gency medical system and outside hospitals, as well as
fluid administered after discharge from the ICU, is not
controlled by the study.
Fig. 2 Crystalloid assignment during the trial. During each month of the study, each intensive care unit is assigned to use either 0.9% saline (S) or
balanced crystalloids (B)
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Each day patients receive the crystalloid to which
their ICU is currently assigned. The necessity that an
IV crystalloid be clinically available at all times pre-
cluded the use of washout periods, and patients who
remain in the ICU through a crossover (i.e., from one
calendar month to another) may potentially be ex-
posed to both types of crystalloid. Although this in-
troduces the potential for contamination of study
groups, in a pilot trial at the same institution, the
total volume of nonassigned crystalloid administered
because of the lack of a washout period was <125 ml
per patient [14]. As described in the Statistical ana-
lysis section below, patients will be analyzed in the
group to which they were assigned at the time of
study enrollment in an intention-to-treat fashion. For
example, a patient admitted to an ICU during a month
assigned to saline will be analyzed in the saline group even
if that patient remains in the ICU after the ICU switches
assignment to balanced crystalloids.
Data collection
In this pragmatic trial, we are using data collected in
routine clinical care and electronically extracted from
the electronic health record (EHR) (see Additional
file 2). All data are stored confidentially in an institu-
tional patient data management system. Data collected
include prestudy renal function; demographic character-
istics, admitting location and diagnosis, and severity of
illness at enrollment; receipt of IV crystalloids, other
fluids, and blood products; serum electrolyte and cre-
atinine values; receipt of RRT, mechanical ventilation,
and vasopressors; and vital status and serum creatinine
at hospital discharge. Electronic extraction of these data
from the EHR has previously been validated against the
reference standard of two-physician manual chart
review [23]. For all patients who receive new RRT, study
personnel will perform manual chart review to confirm
the absence of prior RRT and identify the indication for
RRT.
Fig. 3 Flow diagram of progress of patients through the trial. ICU Intensive care unit
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Primary outcome
The primary outcome will be the proportion of patients
meeting one or more criteria for MAKE30: in-hospital
mortality, receipt of new RRT, or persistent renal dysfunc-
tion defined as a final inpatient serum creatinine value
≥200% of baseline [23–25]. In-hospital mortality will be
defined as death due to any cause prior to hospital dis-
charge censored at 30 days after ICU admission. Receipt
of new RRT will be defined as receipt of any modality of
RRT between ICU admission and the first of hospital dis-
charge or 30 days among patients not known to have re-
ceived RRT prior to ICU admission. Persistent renal
dysfunction will be defined as a final serum creatinine
value before hospital discharge (censored at 30 days after
enrollment) ≥200% of the baseline creatinine value. The
value for baseline serum creatinine will be determined
using a previously described hierarchical approach [23].
The lowest serum creatinine between 12 months and 24 h
prior to hospital admission will be used when available. If
no such creatinine value is available, the lowest creatinine
value between 24 h prior to hospital admission and the
time of ICU admission will be used. If no creatinine value
is available between 12 months prior to hospital admission
and the time of ICU admission, a baseline creatinine value
will be estimated using a previously described formula
[creatinine = 0.74 − 0.2 (if female) + 0.08 (if African Ameri-
can) + 0.003 × age (in years)] [26]. Patients known to have
received RRT prior to enrollment will be considered ineli-
gible to meet criteria for new RRT or persistent renal dys-
function, but they may qualify for MAKE30 by
experiencing in-hospital mortality.
Secondary outcomes
Secondary outcomes will include additional clinical out-
comes, additional renal outcomes, and biochemical out-
comes. Additional clinical outcomes will include in-hospital
mortality before ICU discharge, before 30 days, and before
60 days, as well as ICU-free days, ventilator-free days,
vasopressor-free days, and RRT-free days, all through
28 days after enrollment. Additional renal outcomes will in-
clude new RRT receipt, persistent renal dysfunction, stage 2
or higher AKI according to Kidney Disease: Improving
Global Outcomes (KDIGO) creatinine criteria [27], highest
serum creatinine value, change from baseline creatinine to
highest creatinine, final serum creatinine value before
hospital discharge, and duration of new RRT. Biochemical
outcomes will include serum values for sodium, potassium,
chloride, bicarbonate, blood urea nitrogen, and creatinine
from enrollment through day 30.
Power calculation
On the basis of data from the study ICUs in the 1 year
prior to the trial, we anticipate the planned study
duration (Fig. 2) will result in enrollment of around
14,000 patients with an overall rate of MAKE30 around
15%. Enrollment of 14,000 patients will provide 90%
power at an α level of 0.05 to detect an absolute differ-
ence between the saline and balanced crystalloid groups
in MAKE30 of 1.9%, as well as a relative risk reduction
of 12%, which is comparable to the 12% relative risk re-
duction for in-hospital mortality reported in a recent pilot
trial [13] (additional details in Additional file 2).
Data and safety monitoring board and interim analysis
A DSMB was appointed to oversee the conduct of the
trial and review two interim analyses. The DSMB is
comprised of two academic intensivists outside the study
institution who are experienced in the conduct of
clinical trials in critical illness. The first interim analysis
occurred 6 months after study initiation, examining
patients enrolled between 1 June 2015 and 30 November
2015. The second interim analysis occurred halfway be-
tween the first interim analysis and the end of the trial,
examining patients enrolled between 1 June 2015 and 31
July 2016 (additional details in Additional file 2). Both
interim analyses used the same stopping criteria:
The stopping boundary for efficacy will be met if (1)
the unadjusted difference in the incidence of the
primary outcome (MAKE30) between study groups is
greater than or equal to 2.6% with a P value less than
0.001 and (2) the P value is less than 0.001 for the
difference between study groups in the incidence of
either in-hospital mortality or receipt of new RRT.
Because even small differences between groups would
be clinically meaningful, and given the importance of
determining with as much certainty as possible
whether balanced crystalloids are superior to saline, a
futility stopping boundary will not be employed. Use of
the conservative Haybittle-Peto boundary (P < 0.001)
will allow the final analysis to be performed using an
unchanged level of significance (P = 0.05).
At the time of submission of the manuscript of this
report, both interim analyses had been completed, and
the DSMB had recommended continuing the trial to
completion. In addition, the DSMB is available to evalu-
ate adverse events or serious adverse events during the
conduct of the trial. In cases of serious adverse events,
the DSMB has the ability to pause the trial to investigate
possible safety issues and suggest changes to the design
of the study to abrogate any safety issues.
Statistical analysis principles
All analyses will be performed using R version 3.2.0
software (R Foundation for Statistical Computing,
Vienna, Austria). To maximize transparency and
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reproducibility, a complete version of the R code that
will be used to analyze the final study data is avail-
able in Additional file 3. This ensures that (1) statis-
tical reviewers or external investigators will be able to
replicate the prespecified analysis of the trial inde-
pendently and (2) any changes or additions to the
statistical analysis introduced by investigators or re-
viewers after completion of enrollment will be evident
as differences between the prespecified code and the
analysis code included with the final publication.
All analyses will be conducted at the level of the indi-
vidual patient during an individual hospitalization in an
intention-to-treat fashion unless otherwise specified.
Continuous variables will be reported as mean ± SD,
mean and 95% CI, or median and IQR; categorical vari-
ables will be reported as frequencies and proportions.
Between-group comparisons will be made with the
Mann-Whitney rank-sum test for continuous variables,
the chi-square test for categorical variables, generalized
estimating equations for repeatedly measured variables,
and generalized linear mixed-effects models for analyses
of the primary and secondary outcomes. A two-sided P
value <0.05 will be considered statistically significant.
Analytic rationale
In the setting of a large, pragmatic trial enrolling every
adult admitted to the five participating ICUs, the
SMART study population will contain a wide spectrum
of (1) exposure to the study intervention, (2) baseline
risk of the primary outcome, and (3) physiologically dis-
tinct patient subgroups. The primary and secondary ana-
lyses evaluate the effect of the intervention overall and
across the spectrum of exposure to crystalloid, baseline
risk of MAKE30, and patient subgroups.
Primary analysis
To account for the cluster-level allocation, cluster-level
crossover structure of the trial, the primary analysis will
be an intention-to-treat comparison of the primary out-
come of MAKE30 between the saline and balanced crys-
talloid groups using a generalized linear mixed-effects
model including fixed effects (group assignment, age,
sex, race, source of admission, mechanical ventilation,
vasopressor receipt, diagnosis of sepsis, and diagnosis of
traumatic brain injury) and random effects (ICU)
(additional details in Additional file 2) [28, 29].
Main secondary analysis
Anticipating (1) a wide range in the total volume of crys-
talloid received by study participants and (2) the potential
for greater difference in outcomes between study groups
among those patients who receive larger volumes of crys-
talloid, the main secondary analysis will compare the pro-
portion of patients experiencing MAKE30 in the saline
and balanced crystalloid groups, accounting for patients’
overall volume of isotonic crystalloid received. For this
analysis, we will construct a logistic regression model with
MAKE30 as the outcome and independent variables of
study group, total isotonic crystalloid received between
enrollment and 30 days, and the interaction between the
two (as a cross-product term). This will allow us to deter-
mine whether any volume of crystalloid receipt exists at
which use of balanced crystalloids decreases the risk of
MAKE30 compared with saline.
Given that total crystalloid receipt is a variable that
emerges after enrollment, we will perform sensitivity
analyses (1) using total crystalloid receipt in the 72 h
after enrollment (before incident AKI or death are
likely to have affected isotonic crystalloid administra-
tion), (2) replacing the actual total crystalloid receipt
with predicted total crystalloid receipt based on a
multivariable linear regression model using patient
and ICU characteristics available at the time of en-
rollment derived from crystalloid administration in
the study ICUs in the 1 year prior to the trial, and
(3) comparing outcomes between study groups among
a modified intention-to-treat population of patients
who received at least 500 ml of any study crystalloid
in the 72 h after enrollment.
Additional secondary analyses
We will perform the following additional secondary
analyses:
1. Comparison of secondary outcomes between study
groups.
2. Effect modification by severity of illness and
prespecified subgroups. Using generalized linear
mixed-effects modeling, we will examine the
interaction between crystalloid assignment and the
following baseline variables with respect to the
primary outcome of MAKE30 in the intention-to-
treat population:
a. Source of admission to the ICU (ED, operating
room, transfer from another hospital, hospital
ward, other)
b. Study ICU (medical, surgical, cardiac, neurological,
trauma) (Because cluster cannot be treated as a
random effect for this subgroup, we will use logistic
regression modeling.)
c. Sepsis or septic shock (yes, no)
d. Traumatic brain injury (yes, no)
e. Receipt of mechanical ventilation (yes, no)
f. Receipt of vasopressors (yes, no)
g. Category of renal dysfunction at the time of
enrollment (no renal dysfunction, AKI, chronic
kidney disease, end-stage renal disease receiving RRT)
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h. Risk of in-hospital mortality as predicted by baseline
University HealthSystem Consortium expected
in-hospital mortality (continuous variable ranging
from 0.0 to 1.0)
3. Sensitivity analysis excluding patients admitted in
the week prior to a crossover (“washout”). We will
repeat the primary analysis comparing MAKE30
between study groups in the intention-to-treat
population excluding those admitted in the 7 days
prior to a crossover in ICU crystalloid assignment
(simulating a washout period). Prior data from the
study ICUs suggest that less than 10% of patients
remain in the ICU for longer than 7 days [14].
Excluding those admitted within 7 days of a crossover
in ICU crystalloid assignment will allow use of a
baseline factor to exclude the majority of patients who
would go on to experience a crossover in crystalloid
assignment because of the study design.
4. Sensitivity analysis excluding patients who were
transferred between ICUs or remained in the ICU
through a crossover (“per protocol”). We will repeat
the primary analysis comparing MAKE30 between
study groups in the intention-to-treat population
excluding those who remained in the ICU through
a crossover in crystalloid assignment or who were
transferred between study ICUs.
5. Sensitivity analysis including only each patient’s first
admission to a participating ICU during the study
period. We will repeat the primary analysis
comparing MAKE30 between study groups in the
intention-to-treat population including only the first
ICU admission in the study for each patient.
Corrections for multiple testing
All of the additional secondary analyses will be considered
hypothesis-generating, and no corrections for multiple
comparisons will be performed.
Handling of missing data
Of the components of the MAKE30 primary outcome,
data regarding in-hospital mortality and receipt of new
RRT are not anticipated to be missing for any patients
[14, 23]. In contrast, the persistent renal dysfunction
component of MAKE30 may suffer from missing data
for serum creatinine value at baseline or between enroll-
ment and hospital discharge. In a pilot study of 974 pa-
tients in the same hospital, 31 patients (3.2%) had no
measured serum creatinine between enrollment and hos-
pital discharge [14]. Of these 31 patients, 6 (19.4%) died
within hours of ICU admission and qualified for the
MAKE30 outcome via the in-hospital mortality criteria.
The remaining 25 (80.6%) were low-acuity ICU patients
with a normal creatinine value measured in the 24 h prior
to ICU admission who were discharged from the hospital
within 48 h without another serum creatinine measure-
ment. Of these, 24 had a subsequent outpatient serum
creatinine value measured in the next 90 days, all of which
measurements were in the normal range. Thus, patients
without a serum creatinine measurement between enroll-
ment and hospital discharge who do not experience in-
hospital mortality or new RRT will be classified as not
having experienced the MAKE30 outcome.
With regard to missing data for baseline serum
creatinine, in the same pilot study, 595 (61.0%) of 974
patients had a measured serum creatinine value between
12 months and 24 h prior to hospital admission [14]. Of
those without such a measurement, 259 (68.3%) of 379
had a value measured between 24 h prior to hospital
admission and study enrollment. Only 120 (12.3%) of
974 patients did not have an available serum creatinine
value prior to enrollment. For the main analysis, patients
without a measured serum creatinine value between
12 months prior to hospital admission and enrollment
will have a baseline creatinine value estimated using a
previously described three-variable formula [26]. Mul-
tiple alternative approaches to missing baseline cre-
atinine data will be explored in sensitivity analyses,
including use of complete cases, multivariable single
imputation, and use of the first creatinine after en-
rollment or the highest or lowest creatinine during
the study (see Additional file 2).
Post hoc analyses
In the event that investigators or reviewers introduce
analyses in addition to those described above, these will
be clearly delimitated as post hoc and will be considered
hypothesis-generating.
Presentation of the results
After completion of enrollment and data analysis, the re-
sults of the trial will be communicated to the public
through manuscript publication and submission of the
results to the ClinicalTrials.gov database. Submission for
publication will include public access to the full study
protocol and statistical code. Authorship will be based
on the International Committee of Medical Journal
Editors guidelines, and professional writers will not be
used.
The flow of patients through the study will be pre-
sented in a flow diagram (Fig. 3). Baseline characteristics
will be presented by treatment group, as shown in
Table 1 and Additional file 2: Table S2. The volume of
isotonic crystalloid administered, other fluids, and blood
products administered over time will be presented by
treatment group (Additional file 2: Table S3). Serum
values for sodium, potassium, chloride, bicarbonate,
blood urea nitrogen, and creatinine will be presented in
figures displaying serum values over time by group and
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in tables detailing the incidence of abnormal values
(Additional file 2: Table S4). Clinical and renal outcomes
will be reported by treatment group, as shown in Table 2.
For the primary analysis of the primary outcome, we will
present the unadjusted frequency and proportion of
MAKE30 in each study group, as well as the adjusted
OR, 95% CI, and P value derived from the generalized
linear mixed-effects model. Indications for new RRT are
displayed as in Additional file 2: Table S5. Heterogeneity
of treatment effect analyses will be displayed as locally
weighted scatterplot smoothing (LOESS) curves or par-
tial effect plots for continuous variables and forest plots
for categorical variables.
Discussion
Upon completion, SMART will provide the most com-
prehensive data to date on the comparative effects of
saline versus balanced crystalloids among critically ill
adults. Given that isotonic crystalloid administration
represents the most common intervention provided to
hospitalized patients, saline and balanced crystalloids are
the only available options for isotonic crystalloid adminis-
tration, and also that the relationship between saline and
AKI and death remains unclear, the results of SMART will
have immediate implications for the care of a broad popu-
lation of acutely ill patients. Results showing superior clin-
ical outcomes in the balanced crystalloids group would
provide compelling evidence that balanced solutions
should be considered the preferred isotonic crystalloid for
most acutely ill patients. Better clinical outcomes with sa-
line would cement 0.9% sodium chloride as the first-line
isotonic IV fluid and end the current debate about optimal
crystalloid composition. In this comparative effectiveness
trial of thousands of critically ill adults, a finding of no dif-
ference between groups would still have important impli-
cations for clinical care and future research. In a trial
powered to detect absolute risk reductions as small as 2%
in clinical outcomes, no difference between groups would
imply that the effect of crystalloid choice for the majority
of ICU patients is minimal, and any future research would
need to be focused on select subpopulations.
While designing SMART, we weighed the relative
advantages and disadvantages of multiple study designs,
including a blinded, patient-level randomized trial. A
major challenge to controlled studies of fluid administra-
tion in critical illness is the ability to enroll patients
prior to the period of highest fluid exposure. Because
the majority of fluid is administered as part of resuscita-
tion in the ED and during the first 12 h of ICU admis-
sion, we selected a cluster-level allocation design that
would allow enrollment immediately upon presentation
and coordination between study ICUs and the ED to
maximize exposure to the assigned crystalloid and
minimize exposure to the nonassigned crystalloid. By
basing study group assignment at the unit level, we
ensured delivery of the assigned crystalloid even among
unstable patients for whom fluid was being administered
immediately upon presentation, because the assigned
crystalloid would be the fluid most readily available in
the study unit. The enrollment of all adults admitted to
the participating ICUs examines the effects of saline





Age, years, median [IQR] – –
Male sex, n (%) – –
White race, n (%) – –
Weight, kg, median [IQR] – –
Body mass index, kg/m2, median [IQR] – –
Renal comorbidities, n (%)
Chronic kidney disease, stage 3 or higher – –
Prior RRT receipt – –
Source of admission to ICU, n (%)
Emergency department – –
Transfer from another hospital – –
Hospital ward – –
Another ICU within the hospital – –
Operating room – –
Outpatient – –






Admitting diagnosis, n (%) – –
Sepsis or septic shock – –
Traumatic brain injury
Mechanical ventilation, n (%) – –
Vasopressors, n (%) – –
UHC expected mortality, %, mean (95% CI) – –
Serum creatinine, mg/dl, median [IQR]
Lowest in 12 months prior to hospitalization – –
No. (%) of patients – –
Lowest between hospitalization and ICU admission – –
No. (%) of patients – –
Estimated by three-variable formula – –
No. (%) of patients – –
Study baseline – –
Acute kidney injury, stage 2 or higher – –
ICU Intensive care unit, UHC University HealthSystem Consortium
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versus balanced crystalloids in a real-world clinical
environment, improving the generalizability of the study
findings. Coupling group assignment at the level of the
ICU with relatively short periods (1 month) and frequent
crossovers (at least 11 in each unit) balances baseline
characteristics and cointerventions better than a simple
cluster-randomized trial or before-and-after trial with
the same number of units, decreasing confounding by
seasonal change or trends in usual care over time.
Although blinding of treating clinicians and study
personnel to the assigned intervention would be ideal,
researchers in a prior pilot trial of the same topic found
high rates of provider awareness of crystalloid assign-
ment despite blinding, perhaps owing to the overt effect
of the study crystalloids on clinically available laboratory
values such as serum chloride and bicarbonate [13]. Use
of an objective, patient-centered primary outcome
abstracted automatically from the EHR increases the
pragmatic nature of the design and diminishes the risk
of observer bias.
Several potential threats to the validity of our trial
exist. Including all patients admitted to each study ICU
may produce a patient population with limited average
exposure to the study interventions [13, 14]. On the
basis of our preliminary data from the same units prior
to this study, however, we anticipate that more than
90% of enrolled patients will receive isotonic crystalloid
and at least 25% of patients will receive more than 4 L
of isotonic crystalloid, which is comparable to or
greater than that received in prior positive ICU fluid
trials [30]. Additionally, we have prespecified analyses
to evaluate for a dose-response relationship between
Table 2 Clinical outcomes
Outcome Saline (n =) Balanced (n =) Adjusted OR (95% CI) Adjusted P value
Primary outcome
Major Adverse Kidney Event within 30 days, n (%) – – – –
Secondary clinical outcomes
In-hospital mortality, n (%)
Before ICU discharge – – – –
Before 30 days – – – –
Before 60 days – – – –
ICU-free days, median [IQR] – – – –
Mean ± SD – –
Ventilator-free days, median [IQR] – – – –
Mean ± SD – –
Vasopressor-free days, median [IQR] – – – –
Mean ± SD – –
RRT-free days, median [IQR] – – – –
Mean ± SD – –
Secondary renal outcomes
Serum creatinine, mg/dl
Highest before discharge or day 30, mg/dl, median [IQR] – – – –
Change from baseline to highest value, mg/dl, median [IQR] – – – –
Final value before discharge or 30 days, mg/dl, median [IQR] – – – –
Among survivors, mg/dl, median [IQR] – – – –
Final creatinine ≥200% baseline, n (%) – – – –
Among survivors to hospital discharge – – – –
Among survivors to hospital discharge without new RRT – – – –
Acute kidney injury, stage 2 or higher, n (%) – – – –
Developing after enrollment – – – –
Receipt of new RRT, No. (%) – – – –
Duration of in-hospital receipt, days, median [IQR] – – – –
Continued receipt after hospital discharge, n (%) – – – –
ICU Intensive care unit, RRT Renal replacement therapy
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the volume of isotonic crystalloid administered and
clinical outcomes with saline versus balanced crystal-
loid. Similarly, the broad enrollment criteria may pro-
duce a study population at relatively low risk for
adverse clinical outcomes. The anticipated incidence of
the primary outcome of 15%, however, is comparable to
that of other large ICU fluid management trials [30, 31].
Treating clinicians are aware of study group assignment,
which may permit a treatment bias in which clinicians ad-
minister less isotonic crystalloid and/or more nonisotonic
crystalloids when assigned to one of the fluid groups. For
this reason, we will record and report use of not only iso-
tonic crystalloid but also nonisotonic crystalloid, colloid,
and blood products during the trial. Group assignment at
the level of the cluster with multiple cluster-level cross-
overs introduces the possibility for intracluster correlation,
interperiod correlation, and intracluster intraperiod cor-
relation, which may confound the relationship between
group assignment and clinical outcome. In preparatory
analyses using data from more than 10,000 patients admit-
ted in the 1 year prior to the trial, we found the effect of
intracluster correlation to be minimized by the short pe-
riods and frequent crossovers and the effects of intraper-
iod correlation and intracluster intraperiod correlation to
be small (see Additional file 2: Supplemental methods).
Our primary analysis uses a generalized linear mixed-
effects model to account for these aspects of the study
structure. In the absence of a washout period, there will
be carryover of crystalloid administration from one group
assignment into the other; however, on the basis of pilot
data, we anticipate the volume of nonassigned crystalloid
received as a result of carryover will be low [14], and we
prespecify secondary analyses to address the effects of car-
ryover. Finally, although MAKE30 is a recommended out-
come for clinical trials involving AKI [24, 32], use of a
composite outcome presents potential challenges. Unlike
death and new receipt of RRT, whether persistent renal
dysfunction on hospital discharge is a patient-centered
outcome remains a point of discussion. Persistent renal
dysfunction also relies on the availability of serum creatin-
ine measurements at baseline and before hospital dis-
charge, potentially requiring imputation of missing data
for one component of the composite primary outcome.
Perhaps most important, although death, new receipt of
RRT, and persistent renal dysfunction are weighted equally
in the MAKE30 composite outcome, they may not repre-
sent equivalent outcomes to patients or providers. To ad-
dress this, we will provide data on the MAKE30 outcome
overall and for each of its separate components.
Trial status
SMART is an ongoing, pragmatic, cluster-level alloca-
tion, cluster-level crossover trial that will compare saline
to balanced crystalloids with regard to major adverse
kidney events among critically ill adults. Patient enroll-
ment began on 1 June 2015, and enrollment is scheduled
for completion on 30 April 2017.
Additional files
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
Additional file 2: This file contains supplemental tables and methods,
including additional details regarding electronic health record-based data
collection, power calculation, development of the model for the primary
analysis, interim analyses, and handling of missing data for baseline cre-
atinine. (DOCX 88 kb)
Additional file 3: This file contains a .pdf version of the R code that will
be used to analyze the final study data. (PDF 118 kb)
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